Disease Domain | Count |
---|---|
Neoplasms | 2 |
Hemic and Lymphatic Diseases | 1 |
Infectious Diseases | 1 |
Endocrinology and Metabolic Disease | 1 |
Top 5 Drug Type | Count |
---|---|
Biological products | 1 |
Small molecule drug | 1 |
Top 5 Target | Count |
---|---|
IL-17A x TNF | 1 |
FLT3 x JAK1 x JAK2 x Syk | 1 |
Target |
Mechanism IL-17A stimulants [+1] |
Active Org. |
Originator Org. |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. Mexico |
First Approval Date01 Jan 1997 |
Target |
Mechanism FLT3 inhibitors [+3] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date06 Oct 2020 |
Sponsor / Collaborator |
Start Date30 Apr 2019 |
Sponsor / Collaborator |
Start Date11 Mar 2019 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Tuspetinib ( FLT3 x JAK1 x JAK2 x Syk ) | Adult Acute Myeloblastic Leukemia More | Phase 1/2 |
Luxeptinib ( BTK x FLT3 ) | Chronic lymphocytic leukaemia refractory More | Discontinued |
LOR-2501 ( RNR1 ) | Solid tumor More | Discontinued |
APL-581 ( BRD4 x JAK ) | Hematologic Neoplasms More | Discontinued |
APTO-253 ( c-Myc ) | Solid tumor More | Pending |